Chemist Who Explores Cells’ Protein Interactions With Light To Join UF Scripps Biomedical Research
Promising new drugs sometimes fail when they reach clinical trials despite strong early data. A new scientist joining UF Scripps Biomedical Research aims to address this problem with new chemistry tools that map interactions within cells.
Sea Turtle Conservation Gets Boost From New DNA Detection Method
A study led by University of Florida researchers is the first to sequence environmental DNA, or eDNA, from sea turtles — genetic material shed as they travel over beaches and in water. The research project is also the first to successfully collect animal eDNA from beach sand. The techniques could be used to trace and study other kinds of wildlife, advancing research and informing conservation strategies.
UF Scripps Scientists To Receive $15 Million To Help Fight Current and Future Pandemics
Multiple scientists from UF Scripps Biomedical Research will join a massive federal effort to develop antiviral drugs to treat the pandemic coronavirus and other viral threats.
Shoulder Surgeons Perform First U.S. Surgeries Using Exactech’s Next Generation Cage Glenoid
UF Startup Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced successful first surgeries using the Equinoxe® Laser Cage Glenoid, an innovative, next-generation shoulder implant designed to improve glenoid fixation in anatomic total shoulder arthroplasty.
Myrtelle Enters Into a Worldwide Exclusive License Agreement With Rescue Hearing To Develop and Commercialize Gene Therapy for the Treatment of Hearing Loss
Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for rare genetic diseases, today announced that it has entered into a worldwide exclusive licensing agreement with UF Innovate | Accelerate at The Hub alum Rescue Hearing Inc. (RHI) to develop a novel gene therapy for DFNB8 genetic hearing loss.
Zomedica Enters Into Strategic Investment and Potential Collaboration for VetGuardian Monitoring Product Line
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that it has purchased a $1.0 million convertible note from UF startup Structured Monitoring Products, Inc. (SMP), makers of the VetGuardianTM wireless remote pet monitoring platform, and in connection therewith has acquired the option to act as a sales agent for SMP's platform. Under the terms of the agreement, Zomedica will also have the option to acquire the VetGuardian product line for use in Animal Health.
UF Scientists May Have Found a Way to More Efficiently Apply Genome Editing to Plant Breeding
New research led by a University of Florida scientist shows a development regulator can help plants grow. In the bigger picture, the study’s results also may help genome editing and as a result, plant breeding.
Alcyone Presents Preclinical Data on Gene Therapy Programs With the Center for Gene Therapy at the Abigail Wexner Research Institute (AWRI) at ASGCT 2022
Sid Martin Client Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, presented preclinical data showing the Company's partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101 safely and effectively reactivates the inactive X chromosome in a Rett syndrome mouse model and is safe in a preliminary nonhuman primate study at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.
Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System
UF Startup Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System.
AGTC Announces Positive Three-Month Interim Results From Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
